Calls for papers
-
According to ARS Pharmaceuticals, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved 1mg and 2mg doses of neffy epinephrine nasal spray for the treatment of anaphylaxis in people who weigh more than 15 kilograms.… Read more . . .
-
AstraZeneca announced that the FDA has approved the company’s supplemental NDA to add data related to the treatment of mild asthma to the label for Airsupra albuterol / budesonide MDI. In October 2024, AstraZeneca and… Read more . . .
-
Neumifil antiviral nasal spray developer Pneumagen has announced the launch of a platform called NeumoBind for intranasal protein formulations. The company says, “By anchoring proteins in place on a mucosal surface, NeumoBind addresses a critical… Read more . . .
-
According to Corstasis Therapeutics, the FDA has approved the company’s NDA for Enbumyst (RSQ-777) bumetanide nasal spray for the treatment of edema associated with heart, kidney, and liver disease. In January 2025, Corstasis announced that… Read more . . .
-
Inhaled mRNA developer Ethris and CDMO Evonik have announced a new partnership for development and commercialization of a lipid nanoparticle (LNP) platform for delivery of nucleic acid. Ethris’s SNaP LNP technology will become available to… Read more . . .
-
Strides Pharma Science announced a new development agreement between Strides Pharma Global and OINDP specialist CDMO Kenox Pharmaceuticals for “multiple nasal spray products for the US market across diverse therapeutic indications.” The company did not… Read more . . .
-
According to Pulmovant, the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Pulmovant’s inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).… Read more . . .
-
Phase 2 study finds azelastine nasal spray significantly reduced SARS-CoV-2 and rhinovirus infection
Saarland University announced that the Phase 2 CONTAIN study of azelastine nasal spray as a prophylactic against SARS-CoV-2 demonstrated a significant reduction in SARS-CoV-2 infection and also a reduction in rhinovirus infection for subjects using… Read more . . .
-
SpliSense has announced results from the Phase 2 SPL84-002 study of SPL84 inhaled antisense oligonucleotide (ASO) for the treatment of people with cystic fibrosis who carry the 3849+10 Kb C->T mutation in the CFTR gene. The… Read more . . .
-
According to SoftOx Solutions, the company intends to conduct a Phase 1 proof-of-concept dose escalation study of SoftOx inhalation solution (SIS) in cystic fibrosis patients as part of a refocus away from development of SIS… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA